Clinical Trial Update: Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

The Phase 2 trial of antineoplaston therapy for primary central nervous system lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Antineoplaston therapy

Snippet

Sponsor: Burzynski Research Institute | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: WITHDRAWN